Study on Using MRI-Guided Radiation Therapy to Increase Radiation Dose for Unresectable Non-Metastatic Pancreatic Cancer

Program Overview

The purpose of this study is to see if higher doses of radiation, guided by MRI, along with chemotherapy, can better control pancreatic cancer that cannot be surgically removed. Researchers want to find out if this approach is more effective than standard radiation doses used before or after surgery. The study will also look at the side effects of this higher dose radiation. Participants will receive two chemotherapy drugs: Capecitabine, taken orally twice a day on radiation days, and Gemcitabine, given by IV once a week during radiation. All participants will have already received chemotherapy before joining the study.

Description

This study is exploring whether using higher doses of radiation therapy, guided by MRI, can improve treatment outcomes for patients with pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach can better control the cancer compared to standard radiation doses used in other settings. The study will also monitor any side effects from the higher radiation doses.

Participants will receive two chemotherapy drugs during the study: Capecitabine, which is taken as a pill twice a day on the same days as radiation therapy, and Gemcitabine, which is given through an IV once a week during radiation therapy. Before joining the study, all participants will have already completed a course of chemotherapy.

The study aims to deliver higher radiation doses while minimizing the risk of damage to nearby healthy organs. This is done by carefully targeting the radiation to the tumor using MRI guidance. Researchers will assess both immediate and long-term side effects of this treatment approach.

Eligibility Criteria

Locations